Jul. 9 at 8:02 PM
$PSNL $GH $EXAS $TEM
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
Wednesday, 9th July at 4:00 pm
Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types
Personalis, Inc. (NASDAQ: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung and colorectal cancers, and solid tumor immunotherapy monitoring. The addition of CRC follows the presentation of compelling interim analysis results from the VICTORI study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which demonstrated strong performance of NeXT Personal for detecting early signs of residual or recurrent CRC.
Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients experiencing recurrence after initial treatment.
Personalis has amended its agreement with Tempus to further accelerate the adoption of NeXT Personal. The updated terms will:
Expand the collaboration by adding CRC as the fourth indication for which Tempus will serve as Personalis' exclusive commercial partner
Extend the term of the initial agreement to November 2029
Lengthen the period of Tempus' exclusivity for all four indications through 2028
